STOP: an open label crossover trial to study ICS withdrawal in patients with a combination of obesity and low-inflammatory asthma and evaluate its effect on asthma control and quality of life.
Jan A WitteGert-Jan BraunstahlWouter J B BloxSusan C van 't WesteindeJohannes C C M In 't VeenJasper H KappenElisabeth F C van RossumPublished in: BMC pulmonary medicine (2022)
This study yields valuable data on ICS tapering in patients with T2-low asthma and obesity. It informs future guidelines and committees on corticosteroid-sparing algorithms in these patients. Trial registration Netherlands Trial Register, NL8759, registered 2020-07-06, https://www.trialregister.nl/trial/8759 . Protocol version and date: version 2.1, 20 November 2020.
Keyphrases
- phase iii
- study protocol
- phase ii
- chronic obstructive pulmonary disease
- clinical trial
- metabolic syndrome
- lung function
- insulin resistance
- end stage renal disease
- open label
- type diabetes
- randomized controlled trial
- machine learning
- chronic kidney disease
- weight gain
- double blind
- psychometric properties
- deep learning
- electronic health record
- placebo controlled
- cystic fibrosis
- clinical practice
- physical activity
- minimally invasive
- data analysis